Skip to main content
Journal cover image

Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.

Publication ,  Journal Article
Evon, DM; Sarkar, S; Amador, J; Lok, AS; Sterling, RK; Stewart, PW; Reeve, BB; Serper, M; Reau, N; Rajender Reddy, K; Di Bisceglie, AM ...
Published in: J Hepatol
September 2019

BACKGROUND & AIMS: A comprehensive analysis of changes in symptoms and functioning during and after direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection has not been conducted for patients treated in real-world clinical settings. Therefore, we evaluated patient-reported outcomes (PROs) in a diverse cohort of patients with HCV treated with commonly prescribed DAAs. METHODS: PROP UP is a US multicenter observational study of 1,601 patients with HCV treated with DAAs in 2016-2017. PRO data were collected at baseline (T1), early on-treatment (T2), late on-treatment (T3) and 3-months post-treatment (T4). PRO mean change scores were calculated from baseline and a minimally important change (MIC) threshold was set at 5%. Regression analyses investigated patient and treatment characteristics independently associated with PRO changes on-treatment and post-treatment. RESULTS: Of 1,564 patients, 55% were male, 39% non-white, 47% had cirrhosis. Sofosbuvir/ledipasvir was prescribed to 63%, sofosbuvir/velpatasvir to 21%, grazoprevir/elbasvir to 11%, and paritaprevir/ombitasvir/ritonavir + dasabuvir to 5%. During DAA therapy, mean PRO scores improved slightly in the overall cohort, but did not reach the 5% MIC threshold. Between 21-53% of patients experienced >5% improved PROs while 23-36% experienced >5% worse symptoms. Of 1,410 patients with evaluable sustained virologic response (SVR) data, 95% achieved SVR. Among those with SVR, all mean PRO scores improved, with the 5% MIC threshold met for fatigue, sleep disturbance, and functioning well-being. Regression analyses identified subgroups, defined by age 35-55, baseline mental health issues and a higher number of health comorbidities as predictors of PRO improvements. CONCLUSIONS: In real-world clinical practices, we observed heterogeneous patient experiences during and after DAA treatment. Symptom improvements were more pronounced in younger patients, those with baseline mental health issues and multiple comorbidities. LAY SUMMARY: Patients who received direct-acting antiviral medications for hepatitis C at several liver centers in the US did not generally experience significant changes in baseline symptoms during treatment. We observed a full range of patient experiences with some patients experiencing substantial symptom improvements, yet others experiencing less improvements and some even experiencing a worsening of symptoms. The 1,346 patients who were cured of hepatitis C experienced improvements in fatigue, sleep disturbance, and functional well-being, and trends for improved pain and depression; whereas the 64 who were not cured experienced minimal improvements. Clinicaltrial.gov: NCT02601820.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Hepatol

DOI

EISSN

1600-0641

Publication Date

September 2019

Volume

71

Issue

3

Start / End Page

486 / 497

Location

Netherlands

Related Subject Headings

  • Young Adult
  • Valine
  • Uracil
  • Sustained Virologic Response
  • Sulfonamides
  • Sofosbuvir
  • Ritonavir
  • Quinoxalines
  • Prospective Studies
  • Proline
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Evon, D. M., Sarkar, S., Amador, J., Lok, A. S., Sterling, R. K., Stewart, P. W., … Fried, M. W. (2019). Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. J Hepatol, 71(3), 486–497. https://doi.org/10.1016/j.jhep.2019.04.016
Evon, Donna M., Souvik Sarkar, Jipcy Amador, Anna S. Lok, Richard K. Sterling, Paul W. Stewart, Bryce B. Reeve, et al. “Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.J Hepatol 71, no. 3 (September 2019): 486–97. https://doi.org/10.1016/j.jhep.2019.04.016.
Evon DM, Sarkar S, Amador J, Lok AS, Sterling RK, Stewart PW, et al. Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. J Hepatol. 2019 Sep;71(3):486–97.
Evon, Donna M., et al. “Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.J Hepatol, vol. 71, no. 3, Sept. 2019, pp. 486–97. Pubmed, doi:10.1016/j.jhep.2019.04.016.
Evon DM, Sarkar S, Amador J, Lok AS, Sterling RK, Stewart PW, Reeve BB, Serper M, Reau N, Rajender Reddy K, Di Bisceglie AM, Nelson DR, Golin CE, Lim JK, Fried MW. Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. J Hepatol. 2019 Sep;71(3):486–497.
Journal cover image

Published In

J Hepatol

DOI

EISSN

1600-0641

Publication Date

September 2019

Volume

71

Issue

3

Start / End Page

486 / 497

Location

Netherlands

Related Subject Headings

  • Young Adult
  • Valine
  • Uracil
  • Sustained Virologic Response
  • Sulfonamides
  • Sofosbuvir
  • Ritonavir
  • Quinoxalines
  • Prospective Studies
  • Proline